Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes

Key Points

• The study aims to assess the impact of adverse karyotypes on outcomes in secondary acute myeloid leukemia and related conditions.
• Analyzed outcomes of sAML and AML-MRC with an adverse karyotype.
• Evaluated historical data prior to the introduction of CPX-351.
• Established benchmarks for risk stratification based on karyotype.
• Patients with adverse karyotype presented with significantly worse outcomes.
• The study highlights the necessity for improved risk assessment methods.
• Adverse karyotypes serve as critical indicators of poor prognosis.